COMMA 2003

A randomised clinical trial investigating the effect of pexelizumab versus placebo in patients with MI

1 Treatments

<table>
<thead>
<tr>
<th>Studied treatment</th>
<th>pexelizumab 2.0-mg/kg bolus and 0.05-mg/kg per h infusion for 20 hours</th>
</tr>
</thead>
</table>

Control treatment

<table>
<thead>
<tr>
<th>Placebo</th>
</tr>
</thead>
</table>

Concomitant treatments

- |

2 Patients

<table>
<thead>
<tr>
<th>Patients</th>
<th>patients with MI</th>
</tr>
</thead>
</table>

Inclusion criteria

- |

Exclusion criteria

- |

3 Methods

<table>
<thead>
<tr>
<th>Blinding</th>
<th>double blind</th>
</tr>
</thead>
</table>

Design

- |

Centers

- |

Geographical area

- |

Sample size

643 (328 / 315)

ArretTrt1

- |

ArretTrt0

- |

PeriodeInclusion

- |

Hypothese

- |

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cause death</td>
<td>7/328</td>
<td>16/315</td>
<td>0,42</td>
<td>[0,17; 1,04]</td>
</tr>
<tr>
<td>Serious infection</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>severe bleeding</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References

6 Comments